{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:07:09Z","timestamp":1790820429440,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01EN2007A"],"award-info":[{"award-number":["01EN2007A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Stiftung Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["111975"],"award-info":[{"award-number":["111975"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010571","name":"BMBF Berlin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010571","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["STAR Protocols"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.xpro.2024.103199","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T16:25:35Z","timestamp":1721665535000},"page":"103199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Protocol for assessing GD2 on formalin-fixed paraffin-embedded tissue sections using immunofluorescence staining"],"prefix":"10.1016","volume":"5","author":[{"given":"Sareetha","family":"Kailayangiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Altvater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Farwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8672-5285","authenticated-orcid":false,"given":"Claudia","family":"Rossig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xpro.2024.103199_bib1","first-page":"OF1","article-title":"Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers","author":"Fischer-Riepe","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xpro.2024.103199_bib2","first-page":"5914","article-title":"Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients","volume":"44","author":"Schulz","year":"1984","journal-title":"Cancer Res."},{"key":"10.1016\/j.xpro.2024.103199_bib3","doi-asserted-by":"crossref","DOI":"10.1042\/AN20110006","article-title":"Expression of GD2 and GD3 gangliosides in human embryonic neural stem cells","volume":"3","author":"Yanagisawa","year":"2011","journal-title":"ASN Neuro"},{"key":"10.1016\/j.xpro.2024.103199_bib4","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xpro.2024.103199_bib5","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(18)30578-3","article-title":"Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial","volume":"19","author":"Ladenstein","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xpro.2024.103199_bib6","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.1987.5.9.1430","article-title":"Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma","volume":"5","author":"Cheung","year":"1987","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xpro.2024.103199_bib7","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jamaoncol.2018.4005","article-title":"Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial","volume":"4","author":"Kushner","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xpro.2024.103199_bib8","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1158\/1078-0432.CCR-05-2000","article-title":"A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group","volume":"12","author":"Osenga","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xpro.2024.103199_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26754","article-title":"A phase II study of radioimmunotherapy with intraventricular (131) I-3F8 for medulloblastoma","volume":"65","author":"Kramer","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.xpro.2024.103199_bib10","doi-asserted-by":"crossref","first-page":"8112","DOI":"10.3390\/cimb45100512","article-title":"Targeting GD2-Positive Tumor Cells by Pegylated scFv Fragment-Drug Conjugates Carrying Maytansinoids DM1 and DM4","volume":"45","author":"Kalinovsky","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.xpro.2024.103199_bib11","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xpro.2024.103199_bib12","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T\u00a0cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.xpro.2024.103199_bib13","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T\u00a0cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.xpro.2024.103199_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd6169","article-title":"Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T\u00a0cells in patients with neuroblastoma","volume":"12","author":"Straathof","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xpro.2024.103199_bib15","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xpro.2024.103199_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/ijc.1457","article-title":"Targeting of GD2-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes","volume":"94","author":"Rossig","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.xpro.2024.103199_bib17","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.1158\/1078-0432.CCR-08-3163","article-title":"Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T\u00a0cells","volume":"15","author":"Yvon","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xpro.2024.103199_bib18","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/bjc.2012.57","article-title":"The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting","volume":"106","author":"Kailayangiri","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xpro.2024.103199_bib19","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/pbc.26097","article-title":"Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults","volume":"63","author":"Dobrenkov","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.xpro.2024.103199_bib20","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/2326-6066.CIR-15-0230","article-title":"Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas","volume":"4","author":"Long","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xpro.2024.103199_bib21","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/mpo.10151","article-title":"Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor","volume":"39","author":"Modak","year":"2002","journal-title":"Med. Pediatr. Oncol."},{"key":"10.1016\/j.xpro.2024.103199_bib22","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cncr.28461","article-title":"Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma","volume":"120","author":"Roth","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.xpro.2024.103199_bib23","doi-asserted-by":"crossref","first-page":"31592","DOI":"10.18632\/oncotarget.16363","article-title":"GD2 expression in breast cancer","volume":"8","author":"Orsi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.xpro.2024.103199_bib24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/PAI.0000000000000974","article-title":"Expression Analysis of GD2 by Immunohistochemistry in Invasive Breast Carcinoma: Clinical and Pathologic Correlation","volume":"30","author":"Zhong","year":"2022","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.xpro.2024.103199_bib25","article-title":"Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T\u00a0cells in lung cancer","volume":"10","author":"Reppel","year":"2022","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xpro.2024.103199_bib26","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41598-022-05841-4","article-title":"MACSima imaging cyclic staining (MICS) technology reveals combinatorial target pairs for CAR T\u00a0cell treatment of solid tumors","volume":"12","author":"Kinkhabwala","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xpro.2024.103199_bib27","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T\u00a0cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xpro.2024.103199_bib28","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ymthe.2019.02.014","article-title":"EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells","volume":"27","author":"Kailayangiri","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xpro.2024.103199_bib29","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s43018-022-00405-x","article-title":"Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1","volume":"3","author":"Mabe","year":"2022","journal-title":"Nat. Cancer"}],"container-title":["STAR Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666166724003642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666166724003642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T21:31:35Z","timestamp":1762637495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666166724003642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2666166724003642"],"URL":"https:\/\/doi.org\/10.1016\/j.xpro.2024.103199","relation":{},"ISSN":["2666-1667"],"issn-type":[{"value":"2666-1667","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protocol for assessing GD2 on formalin-fixed paraffin-embedded tissue sections using immunofluorescence staining","name":"articletitle","label":"Article Title"},{"value":"STAR Protocols","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xpro.2024.103199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103199"}}